# MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors

> **NCT02699515** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 114 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** MSB0011359C

## Key facts

- **NCT ID:** NCT02699515
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-11
- **Primary completion:** 2022-02-21
- **Final completion:** 2022-02-21
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02699515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02699515, "MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02699515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*